TY - JOUR T1 - How to better communicate exponential growth of infectious diseases JF - medRxiv DO - 10.1101/2020.06.12.20129114 SP - 2020.06.12.20129114 AU - Martin Schonger AU - Daniela Sele Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/03/2020.06.12.20129114.abstract N2 - Exponential growth bias is the phenomenon that humans underestimate exponential growth. In the context of infectious diseases, this bias may lead to failure to understand the effectiveness of non-pharmaceutical interventions (NPIs). Communicating the same scenario in different ways (framing) has been found to have a large impact on people’s evaluations and behavior in the contexts of social behavior, risk taking and health care. We find that framing matters for people’s assessment of the benefits of NPIs. In two commonly used frames, most subjects in our experiment drastically underestimate the number of cases NPIs avoid. Framing growth in terms of doubling times, rather than growth rates, reduces bias. When the scenario is framed in terms of time gained, rather than cases avoided, the median subject assesses the benefit of NPIs correctly. These findings suggest changes that public health authorities can adopt to better communicate the exponential spread of infectious diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementETH Zurich and Swiss National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ETH Zurich Ethics Commmission. Number: 2020-N-36All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the authors. We are uploading the associated data file (Excel) to medrxiv.org. ER -